|
October, 2005
Light Sciences Oncology Funding / Financing Report
Light Sciences Oncology, Inc.
Funding Announcement: October, 2005
Funding Amount: $35 Million Preferred Stock Offering
Funding Round: Series A
Industry: Medical
Products: Light Infusion Technology. Litx, a combination product that contains a light activated drug (LS11)
Light Sciences in Phase III clinical trial for treatment of hepatocellular carcinoma
Light Sciences Corporation is developing Litx for cancer, eye disease and cardiovascular diseases through three subsidiaries: LSO, Visient Therapeutics, Inc. Vascular Reconditioning, Inc.
Founded: 1995
URL: www.LSOncology.com
|
|
